FDA updates EUA for COVID-19 drug

The new indication and updated Emergency Use Authorization for Olumiant (baricitinib) is for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation. Olumiant is the first immunomodulatory treatment for COVID-19 to receive FDA approval.